search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

External validation of four breast cancer risk prediction models for personalized screening in a prospective Dutch screening cohort.

Jim Peters ,
Daniëlle van der Waal ,
Marjanka K Schmidt ,
Carla H van Gils ,
Mireille J M Broeders ,

Abstract

Tailoring breast cancer screening to individual risk can improve its harm-benefit ratio compared to a 'one-size-fits-all' approach. We externally validated four risk prediction models-Gail, BCSC, BOADICEA, and IBIS-using data from the Personalized RIsk-based MAmmography screening (PRISMA) cohort, embedded in the Dutch biennial screening program (inclusion period 2014-2019). We predicted 5-year breast cancer risk for 38,767 participants using questionnaire data (personal, lifestyle, hormonal, family history) and mammogram-derived breast density, measured using Volpara v1.5.5.4. DNA information was not included. Breast cancer diagnoses until October 2023 were ascertained through linkage with the Netherlands Cancer Registry. Performance was evaluated with concordance index (C-index), observed-expected (O/E) ratio, and calibration slope. During a median follow-up of 4.3 years, 609 cancers were diagnosed. Gail performed poorly (C-index 0.56 [95% CI 0.53-0.59], O/E 0.79 [0.71-0.86], slope 0.59 [0.38-0.80]). BCSC, BOADICEA, and IBIS had modest discrimination (C-indices 0.60 [0.57-0.63], 0.60 [0.57-0.63] and 0.61 [0.58-0.63]), with good calibration for BCSC (O/E 0.93 [0.84-1.05], slope 0.99 [0.69-1.23]) and BOADICEA (O/E 0.96 [0.86-1.06], slope 0.78 [0.57-0.95]). IBIS overpredicted risk (O/E 0.71 [0.56-0.70], slope 0.66 [0.47-0.80]). These results suggest that traditional models have limited accuracy, and better-performing models are needed to realize the potential of personalized screening in nationwide programs.

More about this publication

NPJ breast cancer

Volume 12
Issue nr. 1
Publication date 31-07-2026

Full text links

Publisher website (DOI) 10.1038/s41523-026-01017-9
Europe PubMed Central 43052333
Pubmed 43052333

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.